Q-omics provides the consensus-scored CNTN5 profile across patient tissues and cancer cell-line models. CNTN5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CNTN5 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CNTN5 RNA expression shows 14,071 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, THCA, and THYM as cancer lineages where CNTN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNTN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNTN5 survival associations across molecular data types. CNTN5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNTN5 RNA expression–survival associations across cancer types. High CNTN5 expression shows unfavorable associations in MESO, HNSC, ACC, KICH, COAD and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CNTN5 RNA expression.
This table summarizes CNTN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CNTN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNTN5 shows lower tumor expression in THCA, KICH, KIRC and KIRP and higher tumor expression in HNSC and LUSC. The THCA box plot shows higher CNTN5 RNA expression in normal versus tumor tissue (log2 FC = −2.234, t-test p < 0.001).
This table shows molecular features associated with CNTN5 in patient tissues and cancer cell lines. In patient samples, CNTN5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CNTN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
